PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

Detalles Bibliográficos
Autores principales: Wei, X., Wang, L., Liang, J., Shen, H., Li, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429634/
http://dx.doi.org/10.1097/01.HS9.0000851408.09459.79
_version_ 1784779516354232320
author Wei, X.
Wang, L.
Liang, J.
Shen, H.
Li, J.
author_facet Wei, X.
Wang, L.
Liang, J.
Shen, H.
Li, J.
author_sort Wei, X.
collection PubMed
description
format Online
Article
Text
id pubmed-9429634
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94296342022-08-31 PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA Wei, X. Wang, L. Liang, J. Shen, H. Li, J. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429634/ http://dx.doi.org/10.1097/01.HS9.0000851408.09459.79 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Wei, X.
Wang, L.
Liang, J.
Shen, H.
Li, J.
PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
title PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
title_full PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
title_fullStr PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
title_full_unstemmed PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
title_short PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
title_sort pb2144: pearl: a study to assess the efficacy and safety of penpulimab plus lenalidomide, rituximab, gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large b cell lymphoma
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429634/
http://dx.doi.org/10.1097/01.HS9.0000851408.09459.79
work_keys_str_mv AT weix pb2144pearlastudytoassesstheefficacyandsafetyofpenpulimabpluslenalidomiderituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma
AT wangl pb2144pearlastudytoassesstheefficacyandsafetyofpenpulimabpluslenalidomiderituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma
AT liangj pb2144pearlastudytoassesstheefficacyandsafetyofpenpulimabpluslenalidomiderituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma
AT shenh pb2144pearlastudytoassesstheefficacyandsafetyofpenpulimabpluslenalidomiderituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma
AT lij pb2144pearlastudytoassesstheefficacyandsafetyofpenpulimabpluslenalidomiderituximabgemcitabineandoxaliplatininpatientswithrelapsedrefractorydiffuselargebcelllymphoma

Ejemplares similares